Alterity Therapeutics up big on advancement of ATH434 for Parkinsonian disorderJun. 30, 2020 6:24 AM ETAlterity Therapeutics Limited (ATHE)By: Mamta Mayani, SA News Editor2 CommentsAlterity Therapeutics (NASDAQ:ATHE) is up 71% premarket after receiving FDA guidance on a development pathway for ATH434 (previously PBT434), the company's lead compound for the treatment of Multiple System Atrophy (MSA), a Parkinsonian disorder, including feedback on the design of a Phase 2 trial.Alterity reached agreement with the agency on the non-clinical investigations required to support the mid-stage study, along with patient population, safety monitoring plan, and strategy for evaluating drug exposure during the trial.The agency and Alterity will work together to develop an endpoint that is best suited for the MSA patients.The company is also pursuing approvals in Europe and Australia.
https://seekingalpha.com/news/3587207-alterity-therapeutics-up-big-on-advancement-of-ath434-for-parkinsonian-disorder
Ann: Meeting with US FDA provides development path for ATH434, page-8
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $4.579K | 1.526M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 749591 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 133062022 | 26 |
View Market Depth
| Last trade - 14.03pm 13/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |